Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

BACKGROUND: Rituximab (RTX), a CD20 depleting agent, is a frequently used off-label treatment for multiple sclerosis (MS), while mitoxantrone (MTX) is approved, albeit rarely used for active relapsing MS (RMS). However, observational data comparing RTX and MTX effectiveness and safety are scarce. OB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Chronic Dis
Main Authors: Zrzavy, Tobias, Daniels, Esther, Stuka, Niklas, Weber, Dennis, Winkelmann, Alexander, Rauschka, Helmut, Hecker, Michael, Aboulenein-Djamshidian, Fahmy, Meister, Stefanie, Leutmezer, Fritz, Berger, Thomas, Bsteh, Gabriel, Zettl, Uwe Klaus, Rommer, Paulus
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323410/
https://ncbi.nlm.nih.gov/pubmed/34377385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406223211024366
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados